1. Increasing cord blood cell dose |
· Improved CB collection, processing, freezing, and thawing. |
· Consecutive infusion of two CBUs (RS; Prospective phase II/III clinical trials; Clinical use). |
· Ex vivoexpansion of CB (Phase I/II/III clinical trials). |
· Infusion of CBU with third-party donor cells (Phase II clinical trials). |
2. Improved delivery and homing HSC to bone marrow niche |
· Direct intra-bone infusion of CB (Phase I/II clinical trials). |
· Inhibition of CD26 peptidase (Phase II clinical trials). |
· Ex vivo Fucosylation of CB HSC/HPC (Phase I/II clinical trials). |
3. Improved selection of CBU |
·Enhanced HLA-matching (RS; PSO). |
·Detection of donor specific HLA-antibodies (RS; PSO). |
·Use of KIR matching (RS). |
4. Modification of transplant protocol |
· Using reduced intensity conditioning (RS; Prospective phase II/III clinical trials; Clinical use). |
· Modification of graft-versus-host disease prophylaxis (RS; PSO). |
5. Post-transplant use of growth factors/cytokines |
· Administration of granulocyte colony stimulating factor (GCSF) (Regular clinical use). |
· Administration of stem cell factor (SCF) (Pre-clinical studies). |
· Administration of Eltrombopag (Phase II clinical trials). |
6. Infusion of CB with accessory cells |
· Use of Mesenchymal stem cells (Phase I/II clinical trials). |
· Use of regulatory T cells (Phase I/II clinical trials). |